Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by Alba1314on Aug 30, 2018 8:48am
72 Views
Post# 28541268

RE:Perfect Storm

RE:Perfect StormI think's an interesting and plausible idea that iCo could be bought out but I disagree with the $500M. Yes, the market for Amp B is a billion dollar market, but it's only made it passed Phase I. I'm not discounting the success, but no company is going to pay $500M for anb 8M company, regardless of the potential. That's a lot to lose. I could see $30-40M. 

Take a look at the history of Cynapsus Therapeutics. They had great success reformulating a Parkinson's Disease drug. They were bought out for 3x the market share price at the time during Phase III trials. 

Thanks for the post!
<< Previous
Bullboard Posts
Next >>